Skip to content
DataLookout
Menu

NCT06995898

The Vanguard Study: Testing a New Way to Screen for Cancer

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 107 versions: 13 with changes below, 37 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 44 → 49 locations
    • Site contacts updated at 3 of 49 sites
  2. Minor Study sites: 46 to 49
  3. Minor Study sites: 45 to 46
    • Interventions modified
    • Secondary endpoints: details revised at 1 of 20 entries
  4. Minor Interventions: Biospecimen Collection (Procedure), Device Usage (Device), Electronic Health Record Review (Other), Multi-Cancer Detection Test… to Biospecimen Collection (Procedure), Device Usage (Device), Electronic Health Record Review (Other), Multi-Cancer Early Detection Test…
    • Secondary endpoints: details revised at 2 of 20 entries
    • Site contacts updated at 1 of 45 sites
  5. Minor Study sites: 44 to 45
  6. Notable Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 4 of 20 entries
    • Site details revised at 2 of 44 sites
    • Publications: details revised at 1 of 1 entry
  7. Minor Trial sites expanded: 41 → 44 locationsv101
  8. Minor Study sites: 40 to 41v100
  9. Notable Eligibility criteria expanded, about 46 words
    • Study sites: 39 to 40
    v98
  10. Minor Study sites: 38 to 39v97
  11. Minor Study sites: 37 to 38v96
  12. Notable Primary completion pushed from Dec 31, 2027 to Jan 31, 2029
    • Start date: Jun 16, 2025 to Jun 18, 2025
    • Study description expanded, about 64 words
    v94
  13. Minor Study sites: 36 to 37v91
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Feasibility of enrollment onto study
Timeframe: At time of randomization
Proportion of participants who complete baseline and follow-up questionnaires within 60 days of receipt
Timeframe: Up to 3 years
Proportion of participants who provide the required blood sample for year 1 for Multi-Cancer Detection (MCD) testing within 90 days of recommended time point
Timeframe: Up to 2 years
Proportion of participants considered lost to follow-up within 2 years of randomization
Timeframe: Up to 2 years
Representative enrollment
Timeframe: Up to 2 years
Staggered start of intervention arm 2
Timeframe: Up to 1 year

Secondary (20)

Impact of participant blinding
Timely return of MCD test result
Factors contributing to lack of diagnostic resolution of an abnormal MCD test
Contamination
Effects of participant characteristics
Show 15 moreShow less
Diagnostic resolution following an abnormal MCD test result
Time to diagnostic resolution
Participation in standard of care screening
Accuracy of tissue of origin prediction
Complications related to diagnostic evaluation of an abnormal MCD test result
Anxiety and Cancer Worry Questionnaire
Sensitivity of clinical diagnostic performance of each MCD assay
Specificity of each MCD assay
Test positive rates
False positives
(Targeted cancer) Positive predictive value (PPV)
(All cancer) PPV
Interval cancers
Detected cancers
(Targeted cancer) Negative predictive value

Arms and interventions

Arm I (Shield MCD test)Experimental

Participants undergo blood collection for Shield MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.

Arm II (Avantect MCD test)Experimental

Participants undergo blood collection for Avantect MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.

Arm III (Control)Active comparator

Participants undergo blood collection at enrollment and after one year on study.

Procedures: Biospecimen Collection, Multi-Cancer Early Detection Test

Devices: Device Usage

Other: Electronic Health Record Review, Questionnaire Administration

Sites

49 sites in 1 country